Tullinge, Sweden

Stefan Rehnmark

USPTO Granted Patents = 4 

 

 

Average Co-Inventor Count = 3.5

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2011-2023

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Inventor Stefan Rehnmark

Introduction

Stefan Rehnmark is a notable inventor based in Tullinge, Sweden. He has made significant contributions to the field of cancer treatment through his innovative patents. With a total of four patents to his name, Rehnmark's work focuses on the development of therapeutic compositions and methods for treating cancer.

Latest Patents

Rehnmark's latest patents include groundbreaking research on combinations of a tubulin polymerization inhibitor and a poly (ADP-ribose) polymerase (PARP) inhibitor for use in cancer treatment. These methods and combination therapies aim to treat, prevent, and delay the onset and development of cancer. Another significant patent involves the disclosure of new crystalline forms of genistein, which includes various salts and their therapeutic applications. These compositions are designed to provide effective treatment options for patients in need.

Career Highlights

Throughout his career, Stefan Rehnmark has worked with reputable companies such as Axcentua Pharmaceuticals AB and Noviga Research AB. His experience in these organizations has contributed to his expertise in pharmaceutical research and development.

Collaborations

Rehnmark has collaborated with notable colleagues, including Anders Berkenstam and Michael-Robin Witt. These partnerships have further enhanced his research and innovation in the field of cancer therapies.

Conclusion

Stefan Rehnmark's contributions to cancer treatment through his innovative patents and collaborations highlight his importance in the field of medical research. His work continues to pave the way for new therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…